Literature DB >> 17071043

Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer.

M Vermaas1, F T J Ferenschild, C Verhoef, J J M E Nuyttens, A W K S Marinelli, T Wiggers, W J Kirkels, A M M Eggermont, J H W de Wilt.   

Abstract

AIMS: To report the role of total pelvic exenteration in a series of locally advanced and recurrent rectal cancers.
METHODS: In the period 1994-2004, TPE was performed in 35 of 296 patients with primary locally advanced and recurrent rectal cancer treated in the Daniel den Hoed Cancer Center; 23 of 176 with primary locally advanced and 12 of 120 with recurrent rectal cancer. All but one patient received pre-operative External Beam Radiation Therapy (EBRT). After 1997, Intra Operative Radiotherapy (IORT) was performed in case of a resection margin less than 2 mm.
RESULTS: Overall major complication rates were not significantly different between patients with primary and recurrent rectal cancer (26% vs. 50%, p=0.94). The hospital mortality rate was 3%. The 5-year local control and overall survival of patients with primary locally advanced rectal cancer were 88% and 52%, respectively. In patients with recurrent rectal cancer 3-year local control and survival rates were 60% and 32%, respectively. An incomplete resection, preoperative pain and advanced Wanebo stage for recurrent cancer were negative prognostic factors for both local control and overall survival.
CONCLUSION: TPE in primary locally advanced rectal cancer enables good local control and acceptable overall survival, thereby justifying the use of the procedure. Patients with recurrent rectal cancer showed a high rate of major complications, a high distant metastasis rate, and a poor overall survival.

Entities:  

Mesh:

Year:  2006        PMID: 17071043     DOI: 10.1016/j.ejso.2006.09.021

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  29 in total

1.  Total pelvic exenteration for rectal cancer: outcomes and prognostic factors.

Authors:  Trustin S Domes; Patrick H D Colquhoun; Brian Taylor; Jonathan I Izawa; Andrew A House; Patrick P W Luke; Jonathan I Izawa
Journal:  Can J Surg       Date:  2011-12       Impact factor: 2.089

Review 2.  Surgery for recurrent rectal cancer: technical notes and management of complications.

Authors:  A H Mirnezami; P M Sagar
Journal:  Tech Coloproctol       Date:  2010-05-12       Impact factor: 3.781

3.  The feasibility of laparoscopic extended pelvic surgery for rectal cancer.

Authors:  Hayato Nakamura; Keisuke Uehara; Atsuki Arimoto; Takehiro Kato; Tomoki Ebata; Masato Nagino
Journal:  Surg Today       Date:  2015-10-22       Impact factor: 2.549

4.  Systematic review of outcomes following pelvic exenteration for the treatment of primary and recurrent locally advanced rectal cancer.

Authors:  E Platt; G Dovell; S Smolarek
Journal:  Tech Coloproctol       Date:  2018-12-01       Impact factor: 3.781

5.  Laparoscopic salvage surgery for locally recurrent rectal cancer.

Authors:  Toshiya Nagasaki; Takashi Akiyoshi; Masashi Ueno; Yosuke Fukunaga; Satoshi Nagayama; Yoshiya Fujimoto; Tsuyoshi Konishi; Toshiharu Yamaguchi
Journal:  J Gastrointest Surg       Date:  2014-05-17       Impact factor: 3.452

6.  Lateral pelvic lymphadenectomy for low rectal cancer: a META-analysis of recurrence rates.

Authors:  M R Fahy; M E Kelly; T Nugent; E Hannan; D C Winter
Journal:  Int J Colorectal Dis       Date:  2020-11-26       Impact factor: 2.571

7.  Management of locally advanced primary and recurrent rectal cancer.

Authors:  Johannes H W de Wilt; Maarten Vermaas; Floris T J Ferenschild; Cornelis Verhoef
Journal:  Clin Colon Rectal Surg       Date:  2007-08

8.  Layer-oriented total pelvic exenteration for locally advanced primary colorectal cancer.

Authors:  Keiji Koda; Kiyohiko Shuto; Kenichi Matsuo; Chihiro Kosugi; Mikito Mori; Atsushi Hirano; Yukihiko Hiroshima; Kuniya Tanaka
Journal:  Int J Colorectal Dis       Date:  2015-08-09       Impact factor: 2.571

9.  Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer.

Authors:  Hwa Yeon Yang; Sung Chan Park; Jong Hee Hyun; Ho Kyung Seo; Jae Hwan Oh
Journal:  Ann Surg Treat Res       Date:  2015-08-24       Impact factor: 1.859

10.  Total pelvic exenteration for primary and recurrent malignancies.

Authors:  F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.